Abstract: It is the thorough consistency between the pathophysiological pattern of ischemic stroke and the haemostaseological characteristics of LD Heparin 10.5 Kd that confer specificity to the pertinent patent claim. In particular it is specific role of Tissue factor (TF) and its complex with Factor Vila respectively trigging off cerebral thrombogenesis that condition the rationale of LD Heparin in ischemic stroke. It is the TF/F Vila—complex that makes up the adequate substrate for LD Heparin which is rather resistant to the classical antithrombin-mediated influence but primarily responsive to Tissue Factor Pathway Inhibitor (TFPI). Its extraordinary release on LD Heparin in which LMWH (Enoxaparin) is exceeded threefold constitutes the rationale of striking out on the new indication of stroke.

Abstract: The present invention concerns medium molecular weight heparin (MMWH 10.5 kD) for prevention and treatment of venous thromboembolism in malignant disease.

Abstract: The present invention concerns medium molecular weight heparin (MMWH 10.5 kD) for prevention and treatment of venous thromboembolism in malignant disease.

Abstract: A process for prophylaxis and therapy of thrombotic processes includes preparing heparin having an average molecular weight ranging from 10 to 11.5 kd; formulating a pharmaceutical preparation which includes the heparin; and employing the pharmaceutical preparation for prophylaxis and therapy of thrombotic processes. Preferably the heparin has an average molecular weight of 10.5 kd.

Abstract: A method of treatment for Chronic Fatigue Syndrome (CFS) comprising reducing the effect of serotonin by administering a dosage unit comprised of 5HT3-receptor-antagonist in an amount effective to decrease the effect of serotonin.

Abstract: 5HT3-receptor-antagonists for the treatment of CFS (Chronic Fatigue Syndrome) are disclosed.

Abstract: The invention relates to a novel heparin having an average molecular weight within a range of from 10 to 11.5 kd, in particular, an average molecular weight of 10 kd. Said heparin is obtained by controlled depolymerization of unfractionated heparin and subsequent molecular filtration. Said heparin is used for the preparation of a medicament for the prophylaxis and therapy of thrombo-embolic processes and, inter alia, for the inhibition of coagulation in extracorporeal circulations.

Abstract: The thrombolytic effect of the plasminogen activator pro-urokinase is improved synergistically by the co-administration of urokinase. The two components may be administered sequentially or simultaneously, and if simultaneously, either separately or as a mixture. Preferably an initial bolus injection of urokinase is followed by an infusion of pro-urokinase.

Abstract: Pharmaceutical preparations comprising (a) co-dergocrine or a pharmaceutically acceptable acid addition salt thereof and (b) a calcium antagonist or a pharmaceutically acceptable salt thereof, as well as the treatment of hypertension/migraine by co-administration of components (a) and (b), e.g. in the form of a composition as defined.

Abstract: Pharmaceutical preparations comprising (a) co-dergocrine or a pharmaceutically acceptable acid addition salt thereof and (b) a calcium antagonist or a pharmaceutically acceptable salt thereof, as well as the treatment of hypertension/migraine by co-administration of components (a) and (b), e.g. in the form of a composition as defined.

Abstract: The invention provides novel pharmaceutical compositions useful in the treatment of thrombosis in mammals, comprising a mixture of dihydroergotamine or a related ergot alkaloid and heparin.